PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Identifying rectal cancer patients at risk for local recurrence would allow for refinement in the selection of patients who would benefit from preoperative radiotherapy. PIK3CA, KRAS, and BRAF mutations are commonly found in colon cancers, but their prevalence has not been clearly assessed in rectal cancer. In this study, we aim to determine the mutation frequencies of PIK3CA, KRAS, and BRAF and to investigate whether a mutation may be used as a prognostic parameter in rectal cancer patients. Experimental Design: We evaluated DNA mutations in PIK3CA, KRAS, and BRAF in 240 stage I to III rectal tumors obtained from nonirradiated patients from the Dutch Total Mesorectal Excision trial. Results: PIK3CA, KRAS, and BRAF mutations were identified in 19 (7.9), 81 (33.9), and 5 (2.1) rectal cancers. Patients with PIK3CA mutations developed more local recurrences (5-year risks, 27.8 versus 9.4; P = 0.006) and tended to develop these recurrences more rapidly after surgery (median local recurrence-free interval since surgery: 7.9 versus 19.6 months; P = 0.07) than patients without PIK3CA mutations. In multivariate analysis, PIK3CA mutations remained as an independent predictor for the development of local recurrences (hazard ratio, 3.4; 95 confidence interval, 1.2-9.2; P = 0.017), next to tumor-node-metastasis stage. Conclusion: PIK3CA mutations can be used as a biomarker in identifying rectal cancer patients with an increased risk for local recurrences. Currently, our findings suggest that prospective evaluation of PIK3CA mutation status could reduce overtreatment by preoperative radiotherapy for the low-risk patients who might otherwise only experience the side effects. (Clin Cancer Res 2009;15(22):695662)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205 · cited 4×
“teria of the TME trial (3) and of whom fresh-frozen tumor material was”
InfluentialSelf-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Many studies have implicated that PIK3CA mutations play a central role in tumorigenesis through the coordinated phosphorylation of proteins or transcription factors that directly regulate cell proliferation, differentiation, and invasion (13, 16).”
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Peeters, K. C. M. J., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., Rutten, H., Pahlman, L., Glimelius, B., Leer, J. W., et al. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000257358.56863.ce · Cited by 1,191
Self-citationPeeters, K. C. M. J., van de Velde, C. J. H., Leer, J. W. H., Martijn, H., Junggeburt, J. M. C., Kranenbarg, E. K., Steup, W. H., Wiggers, T., Rutten, H. J., & Marijnen, C. A. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.779 · Cited by 943
Self-citationMutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Marijnen, C. A. M., van de Velde, C. J. H., Putter, H., van den Brink, M., Maas, C. P., Martijn, H., Rutten, H. J., Wiggers, T., Kranenbarg, E. K., Leer, J.-W. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.256 · Cited by 650
Self-citation
Cited by
van Gijn, W., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. M.-K., Putter, H., Wiggers, T., Rutten, H. J., Påhlman, L., Glimelius, B., & van de Velde, C. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70097-3 · Cited by 1,888
Self-citationAspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377
“This mutation (c.40G>A, p.V14I) has previously been described in a limited number of colorectal tumors (Ferraz et al., 2004; Ahlquist et al., 2008; He et al., 2009) and may be pathogenic based on studies showing the recombinant protein containing this mutation to have reduced GTPase activity…”
BackgroundCancer immunology—analysis of host and tumor factors for personalized medicine
Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Metadata
- Authors
- He, Y., Van't Veer, L. J., Mikolajewska-Hanclich, I., van Velthuysen, M.-L. F., Zeestraten, E. C. M., Nagtegaal, I. D., van de Velde, C. J. H., & Marijnen, C. A. M.
- Venue
- Clinical Cancer Research
- Published
- 2009-11-11
- Volume
- 15
- Issue
- 22
- Pages
- 6956-6962
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2168280541
- Cited by
- 100
- References
- 7
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1165
- The paper
- He, Y., Van't Veer, L. J., Mikolajewska-Hanclich, I., van Velthuysen, M.-L. F., Zeestraten, E. C. M., Nagtegaal, I. D., van de Velde, C. J. H., & Marijnen, C. A. M. (2009). PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1165
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.